Contents

Ellipses Pharma explores the need and potential for next generation SRIs as well as the global need to keep improving the clinical trial structure and landscape

Phesi considers patient enrolment and retention in clinical trials, with a focus on oncology trials and the challenges facing them

Gilead Sciences considers the current treatments available for blood cancers as well as how these are likely to develop in the future

Charac considers the NHS’s new Pharmacy First scheme, the benefits of the scheme and barriers to its implementation

Cognitant Group explores the need for patient support programmes, and how these can be improved

Pharmafocus considers the current rise of measles cases in the UK and the measures that should be taken to prevent further infections

Page 5 – FDA accepts argenx’ sBLA for Vyvgart Hytrulo for CIDP treatment

Page 7 – ViiV Healthcare announces interim results from phase 3 trial for HIV treatment

Page 9 – AbbVie’s Tepkinly recommended by NICE for SC treatment of DLBCL

Page 11 – BioNTech and Autolus collaborate for CAR T-cell therapies

Our Team

Executive Director
PMGroup Worldwide Ltd
Karl Equi

Group Managing Editor
Iona Everson

Editorial Assistants
Betsy Goodfellow
betsy@pharmafile.com

Sales Manager
Eliot Haynes

Design & Layout
Peter May

Pharmafocus is published by:

Samedan Ltd
Suite E, 11 Bell Yard Mews,
175 Bermondsey Street,
London, SE1 3TN
Tel: +44 (0)20 7724 3456
Fax: +44 (0)20 7403 7747

Subscriptions & Data Management

Curwood CMS Tel: 01580 883840

ISSN: 1465-5403

Pharmafocus is sent free of charge to selected permanent employees of ethical and OTC pharmaceutical and biotech companies. Employees are specifiers from middle and senior management with responsibility for making buying decisions. Selection is at the discretion of the Publisher. Copies are also available on a subscription basis at an annual fee of £115 (UK), £145 (Europe) and £185 (RoW).

All subscriptions payable to Samedan. Back copies can be purchased for £15.00 each. Pharmafocus is published by Samedan Ltd. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form without permission, unless for the purposes of reference and comment.

©2024 Samedan Ltd, Pharmaceutical Publishers

The opinions and views expressed by contributors to this publication are not necessarily those of the Editor or the Publisher and, while every care has been taken in the preparation of the newspaper, the Editor and the Publisher are not responsible for such opinions and views, or for any inaccuracies in the articles. The Publisher is not responsible for any images supplied by contributors. While every care is taken with artwork supplied, the Publisher cannot be held responsible for any loss or damage incurred. The entire content of this publication is protected by copyright. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, by any means – electronic, mechanical, photocopying or otherwise – without the prior permission of the Publisher.